Scott M. Hynes
About
Scott M. Hynes is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Scott M. Hynes has authored 27 papers receiving a total of 596 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 16 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Scott M. Hynes's work include DNA Repair Mechanisms (9 papers), Cancer therapeutics and mechanisms (9 papers) and Lung Cancer Treatments and Mutations (8 papers). Scott M. Hynes is often cited by papers focused on DNA Repair Mechanisms (9 papers), Cancer therapeutics and mechanisms (9 papers) and Lung Cancer Treatments and Mutations (8 papers). Scott M. Hynes collaborates with scholars based in United States, Spain and Germany. Scott M. Hynes's co-authors include Aimee Bence Lin, Ji Lin, Karla Hurt, Filip Jankú, David S. Hong, Emiliano Calvo, Howard A. Burris, Jeffrey R. Infante, Johanna C. Bendell and Donald Richards and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Pharmaceutical Research.
In The Last Decade
Scott M. Hynes
26 papers receiving 595 citations
Peers
Scott M. Hynes
Gilda P. Chau United States
Heidi Simmons United States
Marina Chan United States
Jill Hallin United States
Mick Woodcock United Kingdom
Jarrod R. Tremayne United States
Laurent Antoni United Kingdom
Yuta Adachi Japan
Shany Koren Switzerland
Timothy L. Helms United States
Citations per year, relative to Scott M. Hynes Scott M. Hynes (= 1×)
peers
Gilda P. Chau
Countries citing papers authored by Scott M. Hynes
Since
Specialization
Citations
This map shows the geographic impact of Scott M. Hynes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott M. Hynes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott M. Hynes more than expected).
Fields of papers citing papers by Scott M. Hynes
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Scott M. Hynes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott M. Hynes. The network helps show where Scott M. Hynes may publish in the future.
Co-authorship network of co-authors of Scott M. Hynes
This figure shows the co-authorship network connecting the top 25 collaborators of Scott M. Hynes. A scholar is included among the top collaborators of Scott M. Hynes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott M. Hynes. Scott M. Hynes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Zahir, Hamim, et al.. (2025). Clinical Assessment of the Drug–Drug Interaction Potential of Omaveloxolone in Healthy Adult Participants. The Journal of Clinical Pharmacology. 65(6). 715–730.
2.
Wu, Lucy, et al.. (2025). Effect of a Supratherapeutic Dose of Omaveloxolone on the Corrected QT Interval in Healthy Participants: A Randomized, Double‐Blind, Placebo‐ and Active‐Controlled, Three‐Way Crossover Study. Clinical and Translational Science. 18(2). e70139–e70139.
3.
Pépin, Xavier, et al.. (2024). Understanding the mechanisms of food effect on omaveloxolone pharmacokinetics through physiologically based biopharmaceutics modeling. CPT Pharmacometrics & Systems Pharmacology. 13(10). 1771–1783.
4.
Yang, Eddy S., Éric Deutsch, Mehmet Altan, et al.. (2021). A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma. Radiotherapy and Oncology. 157. 203–209.
5.
Byers, Lauren A., Alejandro Navarro, Eric Schaefer, et al.. (2021). A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer. Clinical Lung Cancer. 22(6). 531–540.
6.
Hong, David S., Kathleen N. Moore, Johanna C. Bendell, et al.. (2019). A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors.. Journal of Clinical Oncology. 37(15_suppl). 3091–3091.
7.
Bendell, Johanna C., Helge Bischoff, Jimmy J. Hwang, et al.. (2019). A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer. Investigational New Drugs. 38(4). 1145–1155.
8.
Patnaik, Amita, Michael S. Gordon, Frank Tsai, et al.. (2018). A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer Chemotherapy and Pharmacology. 82(3). 407–418.
9.
Patel, Manish R., David S. Hong, Johanna C. Bendell, et al.. (2018). A phase 1b dose-escalation study of prexasertib, a checkpoint kinase 1 (CHK1) inhibitor, in combination with cisplatin in patients with advanced cancer.. Journal of Clinical Oncology. 36(15_suppl). 2579–2579.
10.
Laquente, Berta, José A. López-Martín, Donald Richards, et al.. (2017). A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer. 17(1). 137–137.
11.
Infante, Jeffrey R., Amita Patnaik, Claire F. Verschraegen, et al.. (2017). Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 79(2). 315–326.
12.
Wehler, Thomas, Michael Thomas, Christian Schumann, et al.. (2017). A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer. Lung Cancer. 108. 212–216.
13.
Hong, David S., Jeffrey R. Infante, Filip Jankú, et al.. (2016). Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. Journal of Clinical Oncology. 34(15). 1764–1771.
14.
Calvo, Emiliano, Fadi Braiteh, Daniel D. Von Hoff, et al.. (2016). Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors. Oncology. 91(5). 251–260.
15.
Scagliotti, Giorgio V., Jin Hyoung Kang, David C. Smith, et al.. (2016). Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. Investigational New Drugs. 34(5). 625–635.
16.
Doi, Toshihiko, Takayuki Yoshino, Kohei Shitara, et al.. (2015). Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors. Anti-Cancer Drugs. 26(10). 1043–1053.
17.
Wickremsinhe, Enaksha, Scott M. Hynes, Malcolm I. Mitchell, et al.. (2014). Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors. Xenobiotica. 44(9). 827–841.
18.
Calvo, Emiliano, Victor J. Chen, Mark S. Marshall, et al.. (2014). Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer. Investigational New Drugs. 32(5). 955–968.
19.
Hynes, Scott M., et al.. (2013). Importance of Peptide Transporter 2 on the Cerebrospinal Fluid Efflux Kinetics of Glycylsarcosine Characterized by Nonlinear Mixed Effects Modeling. Pharmaceutical Research. 30(5). 1423–1434.
20.
Verschraegen, Claire F., Roger B. Cohen, Anthony J. Olszanski, et al.. (2011). Abstract A86: A phase 1 study of LY2523355, an Eg5 inhibitor, administered on Days 1, 2, and 3 with or without pegfilgrastim in patients with advanced malignancy (NCT01214629).. Molecular Cancer Therapeutics. 10(11_Supplement). A86–A86.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Gilda P. Chau Breakdown of academic impact, for papers by Heidi Simmons Breakdown of academic impact, for papers by Marina Chan Breakdown of academic impact, for papers by Jill Hallin Breakdown of academic impact, for papers by Mick Woodcock Breakdown of academic impact, for papers by Jarrod R. Tremayne Breakdown of academic impact, for papers by Laurent Antoni Breakdown of academic impact, for papers by Yuta Adachi Breakdown of academic impact, for papers by Shany Koren Breakdown of academic impact, for papers by Timothy L. Helms